Email Updates

You are here

HVTN 110

Status
Ongoing
Phase
I
Principal Investigator(s)
Ian Frank
Objective

Study to test different combinations of 3 experimental HIV vaccines. Two of the study vaccines are given as a pill that people will swallow, and contain a live, weakened virus called adenovirus trype 4. The third vaccine is given as an injection. The study tests the safety of the combinations, and the immune responses of the body to the different combinations.

 

*Trial is in follow-up*

Prevention Option(s)
HIV Vaccine
Study Design
Controlled
Randomized
Double-blind
Arms and Assigned Interventions
Products
Ad4
AIDSVAX
gp120
Clade
B
E
March 2015
February 2019
Enrollment
60
18
Years
49
Years
Population
Women
Men
Sites

Hope Clinic of the Emory Vaccine Center CRS

Decatur, Georgia
United States of America

University of Alabama at Birmingham

Birmingham, Alabama
United States of America

Brigham and Women's Hospital CRS

Boston, Massachusetts
United States of America

Fenway Health (FH) CRS

Boston, Massachusetts
United States of America

Columbia P&S CRS

New York, NY
United States of America

New York Blood Center

New York, New York
United States of America

Site(s) - Nashville

Nashville, Tennessee
United States of America

Site(s) - Philadelphia

Philadelphia, Pennsylvania
United States of America

University of Rochester HVTN CRS

Rochester, New York
United States of America

San Francisco Vaccine and Prevention CRS

San Francisco, California
United States of America

Seattle Vaccine Trials Unit

Seattle, Washington
United States of America

Site(s) - Cleveland

Cleveland, OH
United States of America